Can-Fite BioPharma Ltd. announced the publication of a peer-reviewed scientific article demonstrating the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, across multiple major diseases. The article, titled "Adenosine A3 Receptor Agonists as Multisystemic Disease Modifiers: From Molecular Signaling to Clinical Translation," was published in the Biomolecules Journal. This publication represents a significant scientific validation of the company's A3 adenosine receptor (A3AR) platform technology, reinforcing the potential of A3AR agonists to address diseases with significant unmet medical needs.

The review details evidence supporting A3AR agonist activity in a wide range of conditions. Findings from Can-Fite and independent research institutions worldwide indicate that activation of the A3AR modulates key pathological pathways involved in various diseases.

Pnina Fishman, CSO and Chairperson of Can-Fite, stated that the publication provides important scientific validation. She noted that many findings summarized in the review originate from independent research institutions and extend beyond the company's current clinical development programs.

Can-Fite's clinical pipeline currently includes Namodenoson in Phase 3 development for hepatocellular carcinoma, Phase 2 development for pancreatic cancer, and Phase 2b development for MASH. Piclidenoson is being evaluated in a pivotal Phase 3 study in psoriasis. The publication supports the company's strategy of leveraging A3AR agonists as a platform technology applicable to multiple therapeutic indications.

Can-Fite BioPharma Ltd. is set to present its late-stage clinical pipeline and pursue licensing opportunities at the BIO International Convention 2026 in San Diego. The company will conduct partnering meetings from June 22 to June 25, 2026, to discuss commercialization strategies for its proprietary small-molecule drugs targeting oncological and inflammatory diseases. This engagement is critical for maximizing the global value of its clinical-stage assets through strategic partnerships.

The company's lead drug candidate, Namodenoson, is currently in a pivotal Phase III study for advanced hepatocellular carcinoma (HCC). Additionally, it is being evaluated in pancreatic cancer following a successful Phase IIa study and is undergoing a Phase IIb study for MASH. Can-Fite's other primary candidate, Piclidenoson, is in a pivotal Phase III study for psoriasis and is preparing for a Phase II study in Lowe Syndrome, a rare genetic disease.

Can-Fite's proprietary A3 adenosine receptor (A3AR) platform technology underpins its pipeline of orally administered therapies. The platform has demonstrated a favorable safety profile across more than 1,600 patients treated to date. The company has already established multiple regional licensing agreements, which have generated approximately $20 million in upfront and milestone payments, with potential for additional royalties.

Dr. Sari Fishman, Vice President of Business Development at Can-Fite BioPharma, emphasized the importance of the event for securing collaborations. "BIO International Convention is one of the most important partnering events in the biotechnology industry," said Dr. Fishman. "With two pivotal Phase III programs, an ongoing Phase IIb study in MASH, and additional opportunities in oncology and rare diseases, we look forward to meeting with potential partners to discuss licensing, commercialization, and value-creating collaborations."

Clinical Pipeline Overview

The following table summarizes the current status of Can-Fite's key drug candidates:

Dr. Fishman will be available for partnering meetings throughout the conference to facilitate discussions regarding these assets.